1 completed, 1 recruiting. 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow IRIS Research and Development, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. AB-101, Rituximab, Cyclophosphamide - Rheumatoid Arthritis, Pemphigus Vulgaris | Phase 1 | Recruiting | IRIS Research and Development, LLC | 30 | 2024-05-15 | 2024-09-03 |
| Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS) ACTHar - Psoriatic Arthritis | Phase 4 | Completed | IRIS Research and Development, LLC | 10 | 2018-07-20 | 2021-08-31 |
Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Granulomatosis with Polyangiitis (1) · Lupus Erythematosus, Systemic (1) · Pemphigus (1)
Adrenocorticotropic Hormone (1) · Cyclophosphamide (1) · Rituximab (1) · fludarabine (1)
United States (2)
Guillermo J. Valenzuela, M.D. (1) · Kathy I. Perez, M.D. (1)